BioLineRx
Update in progressBLRX (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
BioLineRx Ltd. is a biopharmaceutical company developing and commercializing therapies for oncology and rare diseases. Its pipeline includes GLIX1, an oral small molecule targeting the DNA damage response in glioblastoma and other cancers; APHEXDA (motixafortide), a peptide in Phase 1 for sickle cell disease and Phase 2b for pancreatic cancer, with a completed Phase 3 for multiple myeloma; and BL-5010, a pen-like applicator for non-surgical skin lesion removal. Founded 2003, based in Hevel Modi’in, Israel.
Company score
- Sentiment
- 0.00
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.14
- Governance
- 0.11
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.07
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.03
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationIsrael
- Founded2003
- Employees20
- Websitewww.biolinerx.com
Identifiers
- ISINUS09071M3043
- FIGIBBG001Y26LK0
- CUSIP09071M106
- CIK0001498403